N/A
N=248,393
Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan
Prostatic Hyperplasia
Bottom Line
View on ClinicalTrials.gov: NCT01323998 ↗Enrolled (actual)
248,393
Serious AEs
—
Results posted
Feb 2012
Primary outcome: Primary: Number of Participants by Treatment Cohort With and Without a Benign Prostatic Hypertrophy (BPH) Diagnosis — 122307; 9456; 3293; 3674 participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- 5ARI (Drug); AB (Drug)
- Age
- Adult, Older Adult · 50+ yrs
- Sex
- Male
- Sponsor
- GlaxoSmithKline
- Primary completion
- Jun 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants by Treatment Cohort With and Without a Benign Prostatic Hypertrophy (BPH) Diagnosis |
122307; 9456; 3293; 3674; 2625; 78324 | — |
Summary
This retrospective study aims to assess treatment patterns within 1 year of initiating BPH treatment, including 5-alpha-reductase inhibitor (5ARI) monotherapy, alpha-blocker (AB) monotherapy, early combination therapy, and delayed combination therapy. The MarketScan database will be utilized for this study (2000-2008)
Eligibility Criteria
Inclusion Criteria
- Male
- aged 50 years or older
- a diagnostic claim for BPH
- at least one prescription claim for a 5ARI or AB in the enrollment period
- continuous eligibility for 6 months prior to and 12 months after index prescription date
Exclusion Criteria
- diagnosis of prostate or bladder cancer during the study period
- any prostate-related surgical procedure within 1 month of the index prescription date
- prescription claim for finasteride 1 mg for male pattern baldness during the study period
Data sourced from ClinicalTrials.gov (NCT01323998). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.